Cerebellar pilocytic astrocytoma

Summary

Cerebellar pilocytic astrocytoma (MONDO:0003168) is a disease. A subtype of cerebellar astrocytoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cerebellar pilocytic astrocytoma
Mondo ID	MONDO:0003168
DOID	DOID:4853
NCIT	C6809
SNOMED CT	277507004
UMLS	C0349620
MedGen	91158
GARD	0023392
Anatomy (UBERON)	UBERON:0002037
Is cancer (heuristic)	no

Also known as: cerebellar pilocytic astrocytoma · cerebellum pilocytic astrocytoma · pilocytic astrocytoma of cerebellum · pilocytic astrocytoma of the cerebellum

Disease family

This is a subtype of cerebellar astrocytoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › cerebellar disorder › cerebellar neoplasm › cerebellar astrocytoma › cerebellar pilocytic astrocytoma

Related subtypes (1): childhood cerebellar astrocytic neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.